Rosa & Co announced today that Mike Reed, Chief Scientist at Rosa, and Michael Weis, Senior Engineer at Rosa, will present “Diabetes models big and small – case examples from 15 years of scoping, developing, and qualifying fit-for-purpose models for QSP research to support drug development” at the Insulin-Glucose Systems Pharmacology FDA workshop in Washington, DC on August 17-18, 2017.
Rosa & Co today announced that Dr. Meghan Pryor will be participating and presenting at the NIH Quantitative Systems Pharmacology and Neurotherapeutics Drug Discovery Workshop in Bethesda, MD, on July 26 – 27. Dr. Pryor will present a poster entitled “A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)”. The poster shows how the PGRN PhysioPD Research Platform has been proven to be useful to simulate the effects of modulating different targets and investigating drug effects on increasing PGRN for the treatment of FTD.
Rosa & Co. LLC is pleased to announce the renewal of a multi-year Research Agreement with Sanofi to provide Rosa’s PhysioPD™ services. The continuing collaboration provides Sanofi with competitive research and development advantage with access to Rosa’s expertise in Quantitative Systems Pharmacology.
Rosa & Co., LLC is proud to welcome Matt Marano as the company's Senior Vice President of Business Development. Mr. Marano will be responsible for leading the continued expansion of the company's worldwide PhysioPD™ commercial strategy. Mr. Marano joins the team from SolveBio (New York, NY) where he served as Senior Vice President of Commercial Development. During his tenure at SolveBio, he directed all sales and business development efforts, specifically focusing on VP- and C-level executives within the Life Sciences industry. Prior to SolveBio, Mr. Marano was Vice President of Sales and Business Development at Gen9 (acquired by Ginkgo Bioworks), a leading next-generation gene synthesis provider, where he successfully led the organization's commercial expansion in the United States, Europe, the Middle East and Africa.
"I am thrilled to be joining the world-class team at Rosa & Co. I've focused much of my career on expanding the commercial presence of some of the Life Science industry's most impactful companies, and Rosa is truly the world leader in Quantitative Systems Pharmacology solutions for the Life Sciences industry," said Matt Marano about his appointment. "We are fortunate that an executive of Matt's stature has joined our team. Together we can further expand our ability to offer PhysioPD Research to clients world-wide," said Founder, Chairman, & CEO Ron Beaver, PhD.
Rosa announces that Mike Reed, Chief Scientist at Rosa will present at the 21st International Congress of Parkinson’s Disease and Movement Disorders meeting on June 7th in Vancouver, BC, Canada. The poster entitled "Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease" describes the development of a Synuclein PhysioMap®, a graphical model architecture to support hypothesis generation and testing. The Synuclein PhysioMap enabled identification of key biological uncertainties and hypotheses and the recommendation of focused laboratory experiments to gain a better understanding of synuclein function in Parkinson’s disease.
Rosa announces that it will present two posters at the Society For Investigative Dermatology (SID) Annual Meeting on March 15th in Portland, OR. The first poster entitled " Mechanistic physiological modeling as a tool for enhancing dermatology research" describes the use of PhysioPD™ Platforms in dermatology drug research and development for acne, atopic dermatitis (AD), psoriasis, skin aging, and erythema indications will be presented by Christina Friedrich, Chief Engineer at Rosa & Co. The second poster entitled “Mechanistic modeling facilitates identification of key pathways involved in dermal aging and potential new targets for anti-aging intervention” is a joint presentation between Proctor & Gamble and Rosa & Co and will be presented by Katherine Kudrycki, Principal Scientist at Rosa. The poster describes the development of a Skin PhysioPD™ Research Platform, a quantitative physiological model representing the physiology of aged dermis and the effects of anti-aging treatments and the use of this Platform to research treatments for photoaged skin.
Rosa and Co. LLC, founded in January 2002, is celebrating its 15-year milestone as an employee-owned drug-development advisory firm. As part of it’s anniversary celebration, Rosa has launched a new website (www.rosaandco.com) to better reflect its industry-leading scientific capabilities and support the development of the broader PhysioPD-style modeling community.
Rosa announces that Christina Friedrich, Chief Engineer at Rosa, will present at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting on March 15th in Washington DC. The poster entitled "Model Qualification Approaches For Quantitative Systems Pharmacology and Mechanistic Physiological Models" compares and contrasts newly proposed Quantitative Systems Pharmacology (QSP) qualification approaches with the use of the Model Qualification Method (MQM) in qualifying QSP/PhysioPD™ models.
Rosa announces that Douglas Chung, Engineer at Rosa, will present at the MathWorks SimBiology User Forum on October 27th in Bellevue, WA. Rosa & Co. developed the RateCalculator, a MATLAB script that calculates a set of reaction rates connected to a species of interest from an existing SimBiology model and plots the resulting values in an organized and informative way. The talk entitled "Computing and Graphing Fluxes to Facilitate QSP/PhysioPD™ Model Development and Calibration" demonstrates the use of this script in the context of a PhysioPD Platform to highlight both the mechanics of using it, and its utility in developing QSP/PhysioPD models. (Abstract)
Rosa & Co. LLC today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016. Rosa’s Dr. Christina Friedrich, Chief Engineer, PhysioPD™ will present a poster on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster entitled “A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)” will demonstrate that the PGRN PhysioPD Research Platform has proven useful to simulate the effects of modulating different targets and model drug effects on increasing PGRN for the treatment of FTD.
Rosa & Co.’s Chief Engineer, PhysioPD™, Dr. Christina Friedrich was recently interviewed for MedicalResearch.com, which publishes exclusive interviews with medical researchers published in major and specialty medical journals. The interview, entitled “Rosa & Co. Develop PhysioMap To Advance Drug Development Programs”, discusses Elan and Rosa’s collaboration in the development of a Synuclein PhysioMap®, a graphical model architecture to support hypothesis generation and testing. This collaboration provided insight into the function of alpha-synuclein in Parkinson's disease.
Rosa announces that Dr. Meghan Pryor, Engineer at Rosa, presented at the MathWorks SimBiology User Forum on September 20th in Boston, MA. Rosa & Co. developed the RateCalculator, a MATLAB script that calculates a set of reaction rates connected to a species of interest from an existing SimBiology model and plots the resulting values in an organized and informative way. The talk entitled "Computing and Graphing Fluxes to Facilitate QSP/PhysioPD™ Model Development and Calibration" demonstrates the use of this script in the context of a PhysioPD Platform to highlight both the mechanics of using it, and its utility in developing QSP/PhysioPD models. (Abstract).
Rosa announces that Dr. Christina Friedrich, Chief Engineer, PhysioPD at Rosa, will present a poster at the 4th World Parkinson Congress on Friday September 23, 2016 at 11:30am to 1:30pm. The poster entitled "Development of a qualitative systems pharmacology model to support hypothesis generation and testing for Parkinson's disease" will demonstrate that the research team identified key biological uncertainties and hypotheses and recommended focused laboratory experiments to gain a better understanding of synuclein function in Parkinson's disease (Press release, poster).
Rosa’s Dr. Michael Weis co-authored an encore poster presentation at the 2016 World Conference on Pharmacometrics (WCoP) entitled: “The International Society of Pharmacometrics’ (ISoP) Special Interest Group (SIG) on Quantitative Systems Pharmacology (QSP): Developing a Community and Advancing a Field”. The poster describes the work of the ISoP QSP SIG to advance the development and utilization of safe and efficacious medicines through the application of QSP.
Rosa announces that Dr. Mike Reed, Chief Scientist, PhysioPD™ at Rosa, will present a poster at the 2016 World Conference on Pharmacometrics (WCoP) on August 24th, 2016 at 12:45 pm – 1:15 pm in Brisbane, Australia. The poster entitled “Application of a quantitative systems pharmacology (QSP) model to evaluate xCT inhibition as a target for central nervous system diseases” will demonstrate that development of a Central Nervous System PhysioPD Research Platform is an illustrative research case of the key role that PhysioPD modeling can play in providing quantitative integration of internal and external knowledge, elucidating mechanistic insight, and supporting decisions in early stage drug discovery. (Press Release, poster).
Rosa's Christina Friedrich, Chief Engineer, PhysioPD™ and MathWorks’ Fulden Buyukozturk, Technical Evangelist, will present a joint webinar on July 13th, 2016 at 10:00 am and 2:00pm EDT. QSP/PhysioPD approaches aim to predict the safety and therapeutic impact of a drug by quantifying the dynamics of its interactions with underlying pathophysiology in order to guide and support drug development. This webinar will use a rheumatoid arthritis (RA) PhysioPD™ Research Platform developed by Rosa & Co to illustrate the utility of key features of MATLAB and SimBiology in exploring pharmaceutical research questions. (press release)
Rosa’s Dr. Michael Weis co-authored a poster at the Population Approach Group, Europe (PAGE) conference entitled: “The International Society of Pharmacometrics’ (ISoP) Special Interest Group (SIG) on Quantitative Systems Pharmacology (QSP): Developing a Community and Advancing a Field”. The poster describes the work of the ISoP QSP SIG to advance the development and utilization of safe and efficacious medicines through the application of QSP.
Rosa's Sharan A. Pagano, Senior Vice President of Scientific Alliances will present at the 7th Annual Shanghai Symposium on Clinical & Pharmaceutical Solutions through Analysis (CPSA Shanghai 2016) on Friday, April 22, 2016. The conference focuses on the current industrial landscape and the global need to bring products to market faster. Ms. Pagano’s talk, entitled “Mechanistic Physiological PhysioPD™ Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach” will focus on the process of creating and conducting research using PhysioPD Platforms to drive scientific innovation in the pharmaceutical industry. PhysioPD Platforms are QSP models designed with multidisciplinary client team input. The PhysioPD research approach is planned to impact client decisions and has been successful across many therapeutic indications.(press release, slides)
Rosa & Co. LLC participated 2016 Roche QSP Methodology Workshop held on February 4 & 5th, 2016 in Basel, Switzerland. Dr. Christina Friedrich, Chief Engineer at Rosa, recently published an article on QSP model qualification, and participated in the workshop that brought together key opinion leaders from industry and academia to make a substantive contribution toward even broader implementation of QSP. The workshop capitalized on the group’s accumulated experience and applications to review and discuss evolving methodologies in the field. (press release)
Rosa & Co.’s Chief Engineer, Dr. Christina Friedrich published an article, “Model Qualification Method for Mechanistic Physiological QSP Models to Support Model-Informed Drug Development” in the CPT: Pharmacometrics & Systems Pharmacology Journal. QSP is being used increasingly by innovative R&D organizations as a powerful research approach that combines available data with scientific knowledge and engineering approaches to facilitate better understanding of biological systems, to improve decision-making, and to reduce risk and increase efficiency in drug discovery and development. Dr. Friedrich’s tutorial draws on years of experience to generate a rigorous, systematic, and broadly applicable Model Qualification Method (MQM) to ensure that QSP models are well-qualified and fit for their intended purposes. The MQM addresses questions of model relevance, scope, uncertainty, biological variability, and use of data, so that model-informed research can proceed with confidence. (Article) (press release)